The prognostic role of TP53 mutations in DLBCL is still debated [3, 44, 46–48] however a recent, large study shows that TP53 disruption is still a negative prognostic factor for survival after the implementation of Rituximab[48]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.